The FDA is extending the comment period on its draft guidance on informed consent in response to a request for more time. Updating a guidance issued in 1998, the draft describes general requirements, basic and additional elements of informed consent, documentation, and responsibilities of the FDA, sponsor, investigator and institutional review board.